platoseedplatoseed
FidoCure® is the leader in Precision Medicine for Canine Oncology.
Backed by Y Combinator · a16z (portfolio)
Cancer is a genetic disease. We know this from decades of human and veterinary cancer research. Precision medicine and targeted therapies are successfully used to treat humans with cancer. At FidoCure®, we bring this approach to the world of veterinary medicine. FidoCure® empowers veterinarians to offer genetic sequencing and targeted therapies to treat dogs with cancer. We are committed to expanding the veterinary oncology toolbox for both diagnostics and therapeutics. Our veterinary partners have treated thousands of dogs over the past 30 years and work closely with the growing FidoCure® network of over 143 clinics and 180 forward-thinking veterinary oncologists throughout the US. Together, we can combat canine cancer!
FidoCure® provides precision medicine for canine cancer by using genomic testing and tumor profiling to guide personalized therapeutic options. It combines real-world genomic evidence with targeted treatments to improve outcomes for dogs with cancer.
The service uses genomic testing and tumor profiling to identify cancer-driving mutations and recommends personalized therapeutic options tailored to each dog's genetic and clinical profile. Veterinarians order genetic test results from FidoCure®, then may prescribe targeted therapies via compounding pharmacies, with FidoCure® providing the underpinning evidence and guidance.
Who it’s for: Veterinarians and pet owners seeking precision, evidence-based approaches to canine cancer treatment.
Claims of real-world evidence, published studies, and press coverage; ongoing product development and clinical adoption by veterinarians
Formerly “The One Health Company” · why startups rename →
Our tests help eradicate cancer by telling doctors whether they got…
Living therapies for pets first, and their people next
